Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the immunomodulator market grown over the years?

The size of the immunomodulator market has seen significant expansion in the past few years. It is projected to increase from $219.94 billion in 2024 to $237.71 billion in 2025, showing a compound annual growth rate (CAGR) of 8.1%. The escalation observed in the historical period can be attributed to advancements in healthcare infrastructure, improved patient awareness, the rise in the elderly population, growing prevalence of autoimmune diseases, and the launch of biologic medicines.

What Is the forecasted market size and growth rate for the immunomodulator market?

The size of the immunomodulator market is predicted to experience significant expansion in the coming years, swelling to $319.67 billion by 2029 at a 7.7% compound annual growth rate (CAGR). This surge during the forecast period can be credited to factors such as an increase in patient preference for non-invasive procedures, regulatory approvals and guidelines, the coverage provided by health insurance for immunomodulatory treatments, the development of and advancement in immunomodulatory drugs, as well as the expenditure in healthcare by the government. The period of forecast also sees major trends like progress in biotechnology and immunotherapy, advances in the research and development pipeline for immunomodulatory drugs, technological advancements, a move towards personalized medicine, and developments in the field of immuno-oncology.

Get your immunomodulator market report here!

https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

What are the major factors driving growth in the immunomodulator market?

The escalation in the prevalence of chronic diseases is predicted to fuel the expansion of the immunomodulator market. Chronic diseases are enduring health problems that usually progress slowly and remain for considerable durations, frequently for years or even spanning a lifetime. Chronic diseases are happening more frequently due to a variety of intertwined factors, such as an aging population, lifestyle choices, genetic predispositions, and the availability and structure of healthcare services. Immunomodulators offer valuable treatment alternatives for managing chronic diseases by adjusting immune responses, diminishing inflammation, preventing organ rejection, increasing immune surveillance, and enhancing symptom management. For example, as per the World Health Organization, a specialized agency of the United Nations based in Switzerland, in September 2023, there were 41 million deaths recorded, 74% of those were the results of non-communicable or chronic diseases every year globally. The list included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. As a result, the increment in chronic diseases is propelling the growth of the immunomodulator market.

What key areas define the segmentation of the global immunomodulator Market?

The immunomodulator market covered in this report is segmented –

1) By Product Type: Immunosuppressants, Immunostimulants, Other Product Types

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Oncology, Respiratory, Human Immunodeficiency Virus, Other Applications

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Immunosuppressants: Corticosteroids, Calcineurin Inhibitors (Tacrolimus, Cyclosporine), Mtor Inhibitors ( Sirolimus, Everolimus), Antimetabolites ( Azathioprine, Methotrexate), Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab), Janus Kinase (Jak) Inhibitors, T-Cell Inhibitors, Other Immunosuppressive Agents

2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins), Monoclonal Antibodies For Immune Stimulation, Vaccines ( Cancer Vaccines, Preventive Vaccines), Adjuvants And Immune Modulatory Agents, Immunostimulatory Agents For Autoimmune Diseases, Toll-Like Receptor (Tlr) Agonists, Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)

3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors), Small Molecule Immunomodulators, Immunotherapy Drugs, Stem Cell-Based Immunomodulators, Immuno-Oncology Drugs, Probiotics And Other Natural Immunomodulatory Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15591&type=smp

What are the top market players propelling the growth of the immunomodulator industry?

Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.

Which trends are expected to transform the immunomodulator market?

Businesses within the immunomodulator industry are zeroing in on the creation of non-immunosuppressive products in order to meet the increasing need for treatments that specifically modulate the immune system without negatively impacting its overall functioning. Non-immunosuppressive is a term used to describe treatments or substances that don’t inhibit or weaken the body’s immune response. For example, Nuvig Therapeutics, Inc., a biotech firm based in the US, launched preliminary clinical trials for NVG-2089, a cutting-edge immune modulator, in February 2024. Specifically designed to offer treatment options for individuals with inflammatory myopathies and acute dermatologic autoimmune conditions, NVG-2089 is a specialized product. This novel, non-immunosuppressive immunomodulator, which has been granted a fast-track designation by the FDA for development in bullous pemphigoid, engages with type II Fc receptors to start an internal regulatory process that diminishes autoimmune irregularities. The principal aim of the research is to evaluate NVG-2089’s safety and tolerability, while secondary aims are centred around pharmacokinetics and pharmacodynamics.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15591

What regions are dominating the immunomodulator market growth?

North America was the largest region in the immunomodulator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Immuno-Oncology Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Immunohematology Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunohematology-global-market-report

Immunosuppressants Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: